Will low-dose lithium help with memory?

In this edition of The People’s Pharmacy, Joe and Teresa Graedon also hear from a reader who found an herbal supplement that made their migraines less intense.

‘How Low Can You Go?’ The Shifting Guidelines for Blood Pressure Control

The number doctors use to demarcate hypertension keeps going down, a trend applauded by many experts, who point to studies ...
Medscape

GLP-1s a Viable Option to Treat, Prevent, a Wide Range of Substance Use Disorders?

Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — ...
Healthline

Type 2 Diabetes Risk Varies Widely in Young Adults. How GLP-1s Can Help

Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified ...
Health

What Happens to Your Blood Sugar When You Take Zinc Regularly

Can zinc lower blood sugar? Here’s how zinc may influence insulin, glucose levels, and who might benefit from supplementation ...

"It's A Constant Battle": People Are Sharing What It's Actually Like To Take GLP-1s Every Day, And Its Eye-Opening

"It showed me what a disadvantage I was at compared to people who don’t have obsessive thoughts about food. It never had ...

Dexcom gives sneak preview of CGM technologies’ long-term health benefits for diabetics

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

Type 2 diabetes risk found to vary widely among adults 18–40 with prediabetes

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, ...
Medscape

Early Introduction of Tirzepatide Yields T2D Benefits

Two-year data from Eli Lilly’s SURPASS-EARLY trial show reduced A1c, body weight, and cardiovascular risk factors.

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered ...

Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

"I Had No Idea That Was A Possible Side Effect": People Are Getting Brutally Honest About Their Experiences On GLP-1s, And Its So Informative

"It showed me what a disadvantage I was at compared to people who don’t have obsessive thoughts about food. It never had ...